Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| No phase specified | Screening | Active | 18 and over | Other | PROPER/IPC 2010-001 NCT01188915 |
Summary
After treatment for Hodgkin disease, secondary cancer, in particular breast cancer induced by treatment, are the first cause of death.
The investigators will estimate the risk to develop breast cancer in this population of women treated for hodgkin disease, and will propose women at high rish to participate in an intensive screening program based on an annual detection based on mammography, echography, and RMI.
Eligibility Criteria
Inclusion Criteria:
- women > 18 years
- treated for Hodgkin disease
- signed informed consent
- high risk of breast cancer
Exclusion Criteria:
- patients unable to have a regular follow-up
Trial Lead Organizations/Sponsors
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes
| F. Eisinger |  | Principal Investigator |
| Dominique GENRE, MD | | Ph: (33) 4 91 22 37 78 |
| Email: bec@marseille.fnclcc.fr | ||
Trial Sites
|
|
|
|
| France | |||
|
|||
| Marseille | |||
|
|||
| François EISINGER, PhD | |||
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01188915
Information obtained from ClinicalTrials.gov on May 29, 2012
Back to Top
